Stay updated on EAGLE Clinical Trial: MEDI4736 & Tremelimumab in Head & Neck Cancer
Sign up to get notified when there's something new on the EAGLE Clinical Trial: MEDI4736 & Tremelimumab in Head & Neck Cancer page.

Latest updates to the EAGLE Clinical Trial: MEDI4736 & Tremelimumab in Head & Neck Cancer page
- ChecktodayChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check7 days agoChange DetectedA sitewide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the study-record error page.SummaryDifference1%

- Check14 days agoChange DetectedThe 403 Forbidden page’s footer revision label changes from v3.7.1 to v3.7.2; the page otherwise remains an error page.SummaryDifference0.2%

- Check21 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study content with a generic error page. The detailed study record and related links are no longer accessible through this page.SummaryDifference16%

- Check49 days agoChange DetectedTel Litwinsky, Israel (52621) was added as a participating site, and Qiryat Krinitzi, Israel (52621) was removed; this updates the geographic footprint of where the trial is conducted.SummaryDifference0.0%

Stay in the know with updates to EAGLE Clinical Trial: MEDI4736 & Tremelimumab in Head & Neck Cancer
Enter your email address, and we'll notify you when there's something new on the EAGLE Clinical Trial: MEDI4736 & Tremelimumab in Head & Neck Cancer page.